STOCKHOLM, 20 November 2020 – Promore Pharma AB (publ) publishes its interim report for the third quarter 2020 on 24 November 2020.
The next day, 25 November, the company will host a webcast telephone conference at 10.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and the recently released HEAL study will be provided. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet, or telephone.
The number of attendees is limited, please register for the conference in advance on the following link:
https://attendee.gotowebinar.com/register/421150747623991564
The conference call will be recorded and made available on the company´s website after the call, and on
Västra Hamnen Corporate Finance Youtube channel.
For additional information, please contact
Jonas Ekblom, VD
Tel: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Tel: [+46] 708 56 52 45
E-mail: erik.magnusson@promorepharma.com
Promore Pharma’s Certified Adviser is Redeye AB.
Phone: [+46] 8 121 576 90
E-mail: certifiedadviser@redeye.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. Ropocamptide (LL-37) has recently finalized a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market